Monocyte Chemoattractant Protein-1 stimulates the differentiation of rat stem and progenitor Leydig cells during regeneration.
Differentiation
Monocyte chemoattractant protein-1
Proliferation
Stem Leydig cells
Testosterone
Journal
BMC developmental biology
ISSN: 1471-213X
Titre abrégé: BMC Dev Biol
Pays: England
ID NLM: 100966973
Informations de publication
Date de publication:
06 10 2020
06 10 2020
Historique:
received:
26
11
2019
accepted:
20
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
28
9
2021
Statut:
epublish
Résumé
Monocyte chemoattractant protein-1(MCP-1) is a chemokine secreted by Leydig cells and peritubular myoid cells in the rat testis. Its role in regulating the development of Leydig cells via autocrine and paracrine is still unclear. The objective of the current study was to investigate the effects of MCP-1 on Leydig cell regeneration from stem cells in vivo and on Leydig cell development in vitro. Intratesticular injection of MCP-1(10 ng/testis) into Leydig cell-depleted rat testis from post-EDS day 14 to 28 significantly increased serum testosterone and luteinizing hormone levels, up-regulated the expression of Leydig cell proteins, LHCGR, SCARB1, CYP11A1, HSD3B1, CYP17A1, and HSD17B3 without affecting progenitor Leydig cell proliferation, as well as increased ERK1/2 phosphorylation. MCP-1 (100 ng/ml) significantly increased medium testosterone levels and up-regulated LHCGR, CYP11A1, and HSD3B1 expression without affecting EdU incorporation into stem cells after in vitro culture for 7 days. RS102895, a CCR2 inhibitor, reversed MCP-1-mediated increase of testosterone level after culture in combination with MCP-1. MCP-1 stimulates the differentiation of stem and progenitor Leydig cells without affecting their proliferation.
Sections du résumé
BACKGROUND
Monocyte chemoattractant protein-1(MCP-1) is a chemokine secreted by Leydig cells and peritubular myoid cells in the rat testis. Its role in regulating the development of Leydig cells via autocrine and paracrine is still unclear. The objective of the current study was to investigate the effects of MCP-1 on Leydig cell regeneration from stem cells in vivo and on Leydig cell development in vitro.
RESULTS
Intratesticular injection of MCP-1(10 ng/testis) into Leydig cell-depleted rat testis from post-EDS day 14 to 28 significantly increased serum testosterone and luteinizing hormone levels, up-regulated the expression of Leydig cell proteins, LHCGR, SCARB1, CYP11A1, HSD3B1, CYP17A1, and HSD17B3 without affecting progenitor Leydig cell proliferation, as well as increased ERK1/2 phosphorylation. MCP-1 (100 ng/ml) significantly increased medium testosterone levels and up-regulated LHCGR, CYP11A1, and HSD3B1 expression without affecting EdU incorporation into stem cells after in vitro culture for 7 days. RS102895, a CCR2 inhibitor, reversed MCP-1-mediated increase of testosterone level after culture in combination with MCP-1.
CONCLUSION
MCP-1 stimulates the differentiation of stem and progenitor Leydig cells without affecting their proliferation.
Identifiants
pubmed: 33023470
doi: 10.1186/s12861-020-00225-1
pii: 10.1186/s12861-020-00225-1
pmc: PMC7541273
doi:
Substances chimiques
Chemokine CCL2
0
Testosterone
3XMK78S47O
Luteinizing Hormone
9002-67-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Subventions
Organisme : National Natural Science Foundation of China
ID : 81671446
Pays : International
Organisme : National Natural Science Foundation of China
ID : 81730042
Pays : International
Organisme : Wenzhou Municipal Science and Technology Bureau
ID : ZS2017009
Pays : International
Références
Ann N Y Acad Sci. 1989;564:86-98
pubmed: 2774419
Mol Cell Endocrinol. 2017 Mar 15;444:1-8
pubmed: 28109954
Exp Cell Res. 2008 Jan 1;314(1):25-37
pubmed: 17727840
Mol Hum Reprod. 2002 Jun;8(6):518-24
pubmed: 12029068
Asian J Androl. 2015 Mar-Apr;17(2):253-60
pubmed: 25337835
Cell Tissue Res. 1985;242(1):145-56
pubmed: 4042133
Endocrinology. 2012 Oct;153(10):5002-10
pubmed: 22865373
J Androl. 1989 Nov-Dec;10(6):472-7
pubmed: 2559907
J Cell Mol Med. 2019 Aug;23(8):5618-5631
pubmed: 31222931
Endocrinology. 2007 Jul;148(7):3214-25
pubmed: 17412805
Biol Reprod. 1999 Jun;60(6):1437-45
pubmed: 10330103
J Endocrinol. 2007 Apr;193(1):53-63
pubmed: 17400803
Front Physiol. 2017 Jun 28;8:430
pubmed: 28701961
J Androl. 1988 Sep-Oct;9(5):343-51
pubmed: 2853150
J Pathol. 2006 Apr;208(5):686-98
pubmed: 16450334
Biol Reprod. 2014 Jun;90(6):123
pubmed: 24740597
Endocrinology. 1989 Jul;125(1):209-16
pubmed: 2661206
Mol Endocrinol. 2006 Feb;20(2):362-78
pubmed: 16166197
Toxicology. 2016 Aug 31;370:31-40
pubmed: 27663972
Cell Mol Life Sci. 1999 Jun;55(6-7):839-56
pubmed: 10412367
Front Physiol. 2017 Nov 13;8:911
pubmed: 29180966
Sci Rep. 2017 Jul 24;7(1):6337
pubmed: 28740105
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2666-71
pubmed: 26929346
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2719-24
pubmed: 16467141
Biol Reprod. 2000 May;62(5):1427-35
pubmed: 10775197
Toxicology. 2013 Apr 5;306:9-15
pubmed: 23391632
Mol Endocrinol. 2003 Nov;17(11):2189-200
pubmed: 12920236
Reproduction. 2013 Apr 15;145(4):371-80
pubmed: 23587774
Biol Reprod. 2011 Dec;85(6):1161-6
pubmed: 21832170
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Endocrinology. 2010 Feb;151(2):748-54
pubmed: 20016029
Mol Endocrinol. 2001 Jan;15(1):172-83
pubmed: 11145748
Mol Endocrinol. 2001 Jan;15(1):184-200
pubmed: 11145749
J Reprod Immunol. 2003 Dec;60(2):143-57
pubmed: 14638441
J Mol Endocrinol. 2006 Apr;36(2):327-36
pubmed: 16595703